Dapagliflozin for the treatment of type 2 diabetes;Dapagliflozina para el tratamiento de la diabetes tipo 2

Annals of Pharmacotherapy

Volumn 46, Issue 4, 2012, Pages 590-598

  Anderson, Sarah L ^a   Marrs, Joel C ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Dapagliflozin; SGLT2 inhibitor; Sodium glucose cotransporter 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

DAPAGLIFLOZIN; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN;

ARTHRALGIA; BACKACHE; BODY MASS; BRONCHITIS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GENITAL TRACT INFECTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INCIDENCE; INFLUENZA; INSULIN RELEASE; INSULIN SENSITIVITY; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84859705044     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q538     Document Type: Review

References (24)

1. WebMD Diabetes Health Center. World diabetes: 366 million cases and counting. http://diabetes.webmd.com/news/20110914/world-diabetes-366-million-cases-and-counting (accessed 2011 Nov 14).
2. National diabetes fact sheet, 2011. Centers for Disease Control and Prevention. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf (accessed 2011 Nov 14).
3. Centers for Disease Control and Prevention. Number of Americans with diabetes expected to double or triple by 2050. http://www.cdc.gov/media/ pressrel/2010/r101022.html (accessed 2011 Nov 14).
4. United Kingdom Prospective Diabetes Study (UKPDS). Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
5. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. UK Prospective Diabetes Study (UKPDS) Group. Diabetes 1995;44:1249-58.
6. Ganong WF. Formation and excretion of urine. In: Review of medical physiology. 22nd ed. New York: Lange Medical Publishing, 2005:699-734.
7. Deetjen P, von Baeyer H, Drexel H. Renal glucose transport. In: Seldin DW, Giebisch G, eds. The kidney: physiology and pathophysiology. 2nd ed. New York: Raven Press, Ltd., 1992:2873-88.
8. Wright EM. Renal Na+-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-8.
9. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Eur J Physiol 2004;447:510-8.
10. van den Heuvel LP, Assink K, Willemsen M, Monnens L. Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 2002;111:544-7.
11. Bristol-Myers Squibb Company, AstraZeneca. NDA 202293 Dapagliflozin: Endocrinologic & Metabolic Advisory Committee background document. Bristol-Myers Squibb, AstraZeneca July 13, 2011. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting Materials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/ UCM262996.pdf (accessed 2011 Nov 14).
12. Kasichayanula S, Liu X, Zhang W, Pfister M, LaCreta FP, Boulton DW. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study. Clin Ther 2011;33:1798-808.
13. Kasichayanula S, Chang M, Hasegawa M, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab 2011;13:357-65.
14. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-6.
15. Kasichayanula S, Liu X, Shyu WC, et al. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 2011;13:47-54.
16. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes. Clin Pharmacol Ther 2009;85:513-9.
17. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-7.
18. Wilding JPH, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus sensitizers: applicability of a novel insulin-dependent treatment. Diabetes Care 2009;32:1656-62.
19. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise. Diabetes Care 2010;33:2217-24.
20. National Institutes of Health. ClinicalTrials. gov. http://clinicaltrials.gov/ ct2/results?term=dapagliflozin+monotherapy (accessed 2011 Nov 14).
21. Nauck MA, Del Prato S, Meier JJ, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011 Aug 4. (Epub ahead of print).
22. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010;375:2223-33.
23. Strojek K, Yoon KH, Hruba V, Elze M, Langkide AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomised, 24-week, doubleblind, placebo-controlled trial. Diabetes Obes Metab 2011;13:928-38.
24. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405-14.